Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

AML Pipeline Products Market Report Overview

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant, and surgery.

The AML pipeline products market research report provides comprehensive information on the therapeutics under development for AML, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for AML and features dormant and discontinued projects.

AML Pipeline Products Market Segmentation by Targets

The key targets in the AML pipeline products market are Receptor Type Tyrosine Protein Kinase FLT3, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47, CD3, Cyclin-Dependent Kinase 9, and DNA among others. Receptor Type Tyrosine Protein Kinase FLT3 is the leading target in the AML pipeline products market.

AML Pipeline Products Market Analysis by Targets

AML Pipeline Products Market Analysis by Targets

For more target insights into the AML pipeline products market, download a free report sample

AML Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the AML pipeline products market are Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cytotoxic To Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, Cyclin Dependent Kinase 9 Inhibitor, and Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor among others. Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor is the leading MoA in the pipeline market.

AML Pipeline Products Market Analysis by Mechanisms of Action

AML Pipeline Products Market Analysis by Mechanisms of Action

For more MoA insights into the AML pipeline products market, download a free report sample

AML Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the AML pipeline products market are intravenous, oral, parenteral, subcutaneous, intratumor, topical, intradermal, intralesional, inhalational, and intraperitoneal among others. Intravenous accounted for the highest number of AML drugs in development in terms of RoA, in 2022.

AML Pipeline Products Market Analysis by Routes of Administration

AML Pipeline Products Market Analysis by Routes of Administration

For more RoA insights into the AML pipeline products market, download a free report sample

AML Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the AML pipeline products market are small molecule, gene-modified cell therapy, monoclonal antibody, cell therapy, monoclonal antibody conjugated, fusion protein, synthetic peptide, subunit vaccine, antisense oligonucleotide, and aptamer among others. The small molecule is the leading molecule type in the AML pipeline drugs market.

AML Pipeline Products Market Analysis by Molecule Types

AML Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the AML pipeline products market, download a free report sample

AML Pipeline Products Market - Competitive Landscape

Some of the leading companies in the AML pipeline products market are Bristol-Myers Squibb Co, Les Laboratoires Servier SAS, Novartis AG, Pfizer Inc, AbbVie Inc, Ascentage Pharma Group International, Daiichi Sankyo Co Ltd, Johnson & Johnson, AstraZeneca Plc, and CSPC Pharmaceutical Group Ltd among others. Bristol-Myers Squibb Co is the leading company in the AML pipeline products market.

AML Pipeline Products Market Analysis by Companies

AML Pipeline Products Market Analysis by Companies

To know more about the leading AML pipeline products market players, download a free report sample

AML Pipeline Products Market Overview

Key Targets Receptor Type Tyrosine Protein Kinase FLT3, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47, CD3, Cyclin Dependent Kinase 9, and DNA
Key MoA Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cytotoxic To Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, Cyclin Dependent Kinase 9 Inhibitor, and Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor
Key RoA Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Topical, Intradermal, Intralesional, Inhalational, and Intraperitoneal
Key Molecule Type Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, Fusion Protein, Synthetic Peptide, Subunit Vaccine, Antisense Oligonucleotide, and Aptamer
Leading Companies Bristol-Myers Squibb Co, Les Laboratoires Servier SAS, Novartis AG, Pfizer Inc, AbbVie Inc, Ascentage Pharma Group International, Daiichi Sankyo Co Ltd, Johnson & Johnson, AstraZeneca Plc, and CSPC Pharmaceutical Group Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of AML.
  • The pipeline guide reviews pipeline therapeutics for AML by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in AML therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates AML therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for AML

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for AML.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the AML pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

2Seventy Bio Inc
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
AbTis Co Ltd
Accro Bioscience Suzhou Co Ltd
Acrotech Biopharma LLC
Actinium Pharmaceuticals Inc
Actinobac Biomed Inc
ADC Therapeutics SA
ADCendo ApS
Adlai Nortye Biopharma Co Ltd
Advanced BioDesign
Advenchen Laboratories LLC
Affichem SA
Affimed GmbH
Agastiya Biotech LLC
Agenus Inc
AIkido Pharma Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV (Inactive)
Akeso Inc
Alaunos Therapeutics Inc
Allogene Therapeutics Inc
ALX Oncology Holdings Inc
Ambrx Biopharma Inc
Amgen Inc
Amogen Pharma Pvt Ltd
Amphivena Therapeutics Inc
Amplia Therapeutics Ltd
Angiocrine Bioscience Inc
ANP Technologies Inc
Antengene Corp Ltd
Antisense Therapeutics Ltd
AnyGen Co Ltd
APIM Therapeutics AS
Aprea Therapeutics Inc
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Aravive Inc
Arcellx Inc
Argenx SE
Armaceutica Inc
Arog Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Ascentage Pharma Group International
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athos Therapeutics Inc
ATP Biopharm
Aucentra Therapeutics Pty Ltd
AUM Biosciences Pte Ltd
Auransa Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
AvenCell Europe GmbH
AVROBIO Inc
Avvinity Therapeutics Ltd
Axter Therapeutics Ltd
BAKX Therapeutics Inc
Bantam Pharmaceutical LLC
Base Therapeutics
Bayer AG
BCI Pharma SA
Beactica Therapeutics AB
Beam Therapeutics Inc
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing JD Biotech Co Ltd
Beijing Konruns Pharmaceutical Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing StarMab BioMed Technology Ltd
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Beroni Group Ltd
Betta Pharmaceuticals Co Ltd
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
Biomea Fusion Inc
BioMed Valley Discoveries Inc
BiOneCure Therapeutics Inc
Bionomics Ltd
BioSight Ltd
Biosplice Therapeutics Inc
BioTheryX Inc
BioXcel Therapeutics Inc
Bivictrix Therapeutics PLC
Blueprint Medicines Corp
BlueSphere Bio Inc
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
BoYen Therapeutics Inc
Bridge Medicines LLC
BridGene Biosciences Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
Canqura Oncology AB
Canthera Discovery
Captor Therapeutics SA
Carbiogene Therapeutics Co Ltd
Cardiff Oncology Inc
Caribou Biosciences Inc
Carrick Therapeutics Ltd
Catalent Inc
CellCentric Ltd
Cellectis SA
Cellerant Therapeutics Inc
Celularity Inc
Celyad Oncology SA
Center for Genetic Engineering and Biotechnology
Centrose LLC
Centrymed Pharmaceutical Inc
Changzhou Qianhong Bio-Pharma Co Ltd
CharlestonPharma LLC
Checkpoint Therapeutics Inc
Cheetah Cell Therapeutics Co Ltd
Chemestmed OU
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
China Immunotech (Beijing) Biotechnology Co Ltd
Chongqing Precision Biotech Co Ltd
Chongqing Zhixiang Jintai Bio-Pharmaceutical Co Ltd
Chordia Therapeutics Inc
Chugai Pharmaceutical Co Ltd
CicloMed LLC
Cleave Therapeutics Inc
Cogent Biosciences Inc
CoImmune Inc
Cornerstone Pharmaceuticals Inc
CRISPR Therapeutics AG
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
CTCELLS Inc
Cue Biopharma Inc
Cullinan Oncology Inc
Curacle Co Ltd
CuronBiotech Inc
Cyclacel Pharmaceuticals Inc
CytoImmune Therapeutics Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
Delta-Fly Pharma Inc
Demuris Ltd
Denovo Biopharma LLC
Deverra Therapeutics Inc
Diaccurate
Diatheva srl
Dimericon Therapeutics AG
DiNonA Inc
Dong Wha Pharma Co Ltd
Duet Therapeutics Inc
Dynamic Cell Therapies Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
Elpis Biopharmaceuticals Corp
Elucida Oncology Inc
Emercell SAS
Eminent Biosciences
EntreChem SL
Enzyme by Design Inc
Epigene Therapeutics Inc
Epizyme Inc
Escend Pharmaceuticals Inc
Etern BioPharma Co Ltd
Eterna Therapeutics Inc
ExCellThera Inc
Exonate Ltd
Expression Therapeutics Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
FatiAbGen Corp
FibroGen Inc
Fimecs Inc
Flavocure Biotech LLC
Fujifilm Holdings Corp
FutureGen Biopharm Technology Co Ltd
Gadeta BV
GammaDelta Therapeutics Ltd
Genentech USA Inc
GeneScience Pharmaceuticals Co Ltd
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Genosco Inc
Genus Oncology LLC
Geron Corp
Gilead Sciences Inc
GlycoMimetics Inc
Glycostem Therapeutics BV
Golden Biotechnology Corp
GPCR Therapeutics Inc
Gracell Biotechnologies Inc
Greenfire Bio LLC
GSK plc
GT Biopharma Inc
Guangzhou Bio-gene Technology Co Ltd
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou DAC Biotech Co Ltd
Hangzhou Puji Yuancheng Biomedical Technology Co Ltd
Hangzhou Qihan Biotechnology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
HEC Pharma Co Ltd
Hefei Cosource Pharmaceutical Inc
Helocyte Biosciences Inc
HemoGenyx Pharmaceuticals Plc
HighPass Bio Inc
Hillstream BioPharma Inc
Hinova Pharmaceuticals Co Ltd
HK inno.N Corp
Horizon Therapeutics Plc
Hoth Therapeutics Inc
Hoverink Biotechnologies Inc
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
HUYA Bioscience International LLC
Hybrigenics SA
I-Mab
iCell Gene Therapeutics LLC
IGM Biosciences Inc
Imago BioSciences Inc
Imbioray (Hangzhou) Biomedicine Co Ltd
ImCheck Therapeutics SAS
Immune Onc Therapeutics Inc
Immune System Key Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
ImmunoAct Pvt Ltd
Immunocore Holdings Plc
ImmunoGen Inc
IN8bio Inc
Inatherys
Incyte Corp
Inflection Biosciences Ltd
Inmune Bio Inc
Innate Pharma SA
InnoCare Pharma Ltd
InnoPharmaScreen Inc
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
InSilico Medicine
Interprotein Corp
Intra-Immusg Pvt Ltd
Invivoscribe Inc
Io Therapeutics Inc
Ipsen SA
Isoprene Pharmaceuticals Inc
Iterion Therapeutics Inc
Jacobio Pharmaceuticals Group Co Ltd
January Therapeutics Inc
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangxi Shanxing Biotechnology Co Ltd
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
KAHR medical Ltd
Kainos Medicine Inc
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
KeViRX Inc
Kiadis Pharma NV
KinaRx LLC
Kintor Pharmaceutical Ltd
KisoJi Biotechnology Inc
Kronos Bio Inc
Kura Oncology Inc
Kurome Therapeutics Inc
Kymera Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Lai Corporation Pty Ltd
LAVA Therapeutics NV
Lead Discovery Center GmbH
Legend Biotech Corp
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Leukos Biotech SL
Lotus Pharmaceutical Co Ltd
LTZ Therapeutics Inc
Lynk Pharmaceutical Hangzhou Co Ltd
Mablink Bioscience
Mabwell Shanghai Bioscience Co Ltd
Machavert Pharmaceuticals LLC
MacroGenics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Maxinovel Pharmaceuticals
MedAbome Inc
MediGene AG
MediSix Therapeutics Pte Ltd
MedPacto Inc
MEI Pharma Inc
Mendus AB
Merck & Co Inc
Merck KGaA
Meryx Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Minneamrita Therapeutics LLC
MiRx Pharmaceuticals LLC
Mito BioPharm LLC
Molecular Partners AG
Molecular Templates Inc
Molecules For Health Inc
Moleculin Biotech Inc
Morphiex Biotherapeutics Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
MyeloRx LLC
Nanchang Hongyi Pharmaceutical Co Ltd
Nanjing IASO Biotherapeutics Co Ltd
Nanjing Ruijie Pharmaceutical Technology Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanoligent SL
NanoPharmaceuticals LLC
NanoValent Pharmaceuticals Inc
Nemucore Medical Innovations Inc
Nerviano Medical Sciences SRL
New Beta Innovation Ltd
Newave Pharmaceutical Inc
NextCure Inc
NGM Biopharmaceuticals Inc
Nkarta Inc
Nohla Therapeutics Inc
Northlake International LLC
Novartis AG
Novelty Nobility Inc
Novorex Inc
Nuvation Bio Inc
Oita University Institute of Advanced Medicine Inc
Omeros Corp
OncoC4 Inc
Oncoheroes Biosciences Inc
Oncolytics Biotech Inc
Oncolyze Inc
OncoMyx Therapeutics Inc
Oncopeptides AB
OncoTartis Inc
Oncotelic Therapeutics Inc
One-Carbon Therapeutics AB
ONK Therapeutics Ltd
Ono Pharmaceutical Co Ltd
Opna Bio SA
Opsyon
Orano Med LLC
Orca Biosystems Inc
Orum Therapeutics Inc
Oryzon Genomics SA
Ossium Health Inc
Otsuka Pharmaceutical Co Ltd
Oxcia AB
Oxford BioMedica Plc
Pacylex Pharmaceuticals Inc
Paean Biotechnology Inc
PCG-Biotech Co Ltd
PDS Biotechnology Corp
PeLeMed Co Ltd
PendreaBio Inc
Penrose Therapeutix LLC
PentixaPharm GmbH
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharma Mar SA
PharmCADD Co Ltd
Pharos iBio Co Ltd
Phebra Pty Ltd
Phi Pharma SA
Phoenix Molecular Designs
PhoreMost Ltd
Picobella LLC
Pimera Inc
PiNK Biopharma Ltd
Pinotbio Inc
Pinteon Therapeutics Inc
Pleco Therapeutics BV
Plexium Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
Primetime Life Sciences LLC
PRISM Pharma Co Ltd
Promutech Pharmaceuticals Inc
Proteintech Group Inc
Protheragen Inc
Provectus Biopharmaceuticals Inc
Provention Bio Inc
PTC Therapeutics Inc
Puretech Health Plc
PYC Therapeutics Ltd
Qilu Pharmaceutical Co Ltd
QLSF Biotherapeutics Inc
Qualigen Therapeutics Inc
Qurient Co Ltd
Race Oncology Ltd
Rain Therapeutics Inc
Rasio Therapeutics Inc
Rasna Therapeutics Inc
Regenacy Pharmaceuticals LLC
ReguGene Co Ltd
Relevant Biosciences Inc
Remedy Plan Inc
Rigel Pharmaceuticals Inc
Roivant Sciences Ltd
Ryvu Therapeutics SA
SA Science Inc
Salarius Pharmaceuticals Inc
Samus Therapeutics Inc
Sandhill Therapeutics Inc
Sanofi
Sapience Therapeutics Inc
Sardona Therapeutics Inc
Sareum Holdings Plc
Schrodinger Inc
Seagen Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Senti Biosciences Inc
SFA Therapeutics Inc
Shanghai icell Biotechnology Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Zeke Biotech Co Ltd
Shattuck Labs Inc
Shengke Pharmaceuticals (Jiangsu) Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shorla Pharma Ltd
Shouyao Holding Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
SideROS
SignalChem Lifesciences Corp
Sinco Pharmaceuticals Holdings Ltd
Sino Biopharmaceutical Ltd
SiNOPSEE Therapeutics Pte Ltd
Sisu Pharma Inc
Smart Immune SAS
Sorrento Therapeutics Inc
SphingoGene Inc
Stelexis Therapeutics LLC
Stemirna Therapeutics Ltd
StingInn LLC
Storm Therapeutics Ltd
Sumitomo Dainippon Pharma Oncology, Inc
Sumitomo Pharma Co Ltd
Sutro Biopharma Inc
SuviCa Inc
Suzhou JiSheng Pharmaceutical Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Synactix Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Syros Pharmaceuticals Inc
Systimmune Inc
T-CURX GmbH
Tacitus Therapeutics Inc
Taivex Therapeutics Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Talem Therapeutics Inc
TC BioPharm Ltd
TCR2 Therapeutics Inc
TeamedOn International Inc
Telios Pharma Inc
Telix Pharmaceuticals Ltd
Tetranov International Inc
Teva Pharmaceutical Industries Ltd
Tiziana Life Sciences Plc
Toko Pharmaceutical Industries Co Ltd
TOLREMO Therapeutics AG
TOT Biopharm Co Ltd
TransThera Sciences (Nanjing) Inc
Treadwell Therapeutics Inc
Triphase Accelerator Corp
TScan Therapeutics Inc
TSD Life Sciences
Tubulis GmbH
UbiVac Inc
UTC Therapeutics Inc
Varian Biopharmaceuticals Inc
Vertex Pharmaceuticals Inc
Veru Inc
Vessel Scientific LLC
Vichem Chemie Research Ltd
Vincerx Pharma Inc
VioQuest Pharmaceuticals Inc (Inactive)
Viracta Therapeutics Inc
Viridian Therapeutics Inc
VM Discovery Inc
Vor BioPharma Inc
Vyriad Inc
Wellington Zhaotai Therapies Ltd
Wigen Biomedicine Technology (Shanghai) Co Ltd
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wyze Biotech Co Ltd
XEME BioPharma Inc
Xencor Inc
XNK Therapeutics AB
Y-mAbs Therapeutics Inc
Yeda Research and Development Company Ltd
Yungjin Pharm Co Ltd
Zenith Epigenetics Ltd
Zentalis Pharmaceuticals Inc
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zovis Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Overview

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Companies Involved in Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Drug Profiles

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, 2022

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the AML pipeline products market?

    The key targets in the AML pipeline products market are Receptor Type Tyrosine Protein Kinase FLT3, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47, CD3, Cyclin Dependent Kinase 9, and DNA among others.

  • What are the key mechanisms of action in the AML pipeline products market?

    The key mechanisms of action in the AML pipeline products market are Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cytotoxic To Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, Cyclin Dependent Kinase 9 Inhibitor, and Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor, among others.

  • What are the key routes of administration in the AML pipeline products market?

    The key routes of administration in the AML pipeline products market are intravenous, oral, parenteral, subcutaneous, intratumor, topical, intradermal, intralesional, inhalational, and intraperitoneal, among others.

  • What are the key molecule types in the AML pipeline products market?

    The key molecule types in the AML pipeline products market are small molecule, gene-modified cell therapy, monoclonal antibody, cell therapy, monoclonal antibody conjugated, fusion protein, synthetic peptide, subunit vaccine, antisense oligonucleotide, and aptamer, among others

  • Which are the leading companies in the AML pipeline products market?

    Some of the leading companies in the AML pipeline products market are Bristol-Myers Squibb Co, Les Laboratoires Servier SAS, Novartis AG, Pfizer Inc, AbbVie Inc, Ascentage Pharma Group International, Daiichi Sankyo Co Ltd, Johnson & Johnson, AstraZeneca Plc, and CSPC Pharmaceutical Group Ltd.

Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.